Earnest Partners LLC Buys 12,500 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Earnest Partners LLC grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 2.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 618,049 shares of the medical research company's stock after acquiring an additional 12,500 shares during the quarter. Bio-Rad Laboratories accounts for approximately 0.9% of Earnest Partners LLC's portfolio, making the stock its 25th largest holding. Earnest Partners LLC owned about 2.21% of Bio-Rad Laboratories worth $203,035,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Venturi Wealth Management LLC boosted its holdings in Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after purchasing an additional 87 shares during the last quarter. GeoWealth Management LLC lifted its position in shares of Bio-Rad Laboratories by 342.9% during the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after buying an additional 72 shares in the last quarter. Picton Mahoney Asset Management boosted its stake in shares of Bio-Rad Laboratories by 55.6% in the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after buying an additional 35 shares during the last quarter. Asset Planning Inc bought a new position in shares of Bio-Rad Laboratories in the fourth quarter valued at approximately $33,000. Finally, UMB Bank n.a. increased its position in shares of Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after acquiring an additional 32 shares during the last quarter. Institutional investors own 65.24% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. StockNews.com downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Royal Bank of Canada reiterated an "outperform" rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, Wells Fargo & Company lowered their target price on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $380.20.

Bio-Rad Laboratories Price Performance

NYSE:BIO opened at $242.22 on Friday. The firm has a market capitalization of $6.78 billion, a price-to-earnings ratio of -3.72 and a beta of 1.12. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The stock has a fifty day moving average of $251.03 and a 200 day moving average of $308.28. Bio-Rad Laboratories, Inc. has a 52-week low of $215.38 and a 52-week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.